The Journal of Infectious Diseases,
Год журнала:
2023,
Номер
228(Supplement_2), С. S136 - S143
Опубликована: Авг. 31, 2023
Understanding
variant-specific
differences
in
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
viral
kinetics
may
explain
transmission
efficiency
and
provide
insights
on
pathogenesis
prevention.
We
evaluated
SARS-CoV-2
from
nasal
swabs
across
multiple
variants
(Alpha,
Delta,
Epsilon,
Gamma)
placebo
recipients
of
the
ACTIV-2/A5401
trial.
Delta
variant
infection
led
to
highest
maximum
load
shortest
time
symptom
onset
peak.
There
were
no
significant
clearance
variants.
Viral
decline
was
biphasic
with
first-
second-phase
decays
having
half-lives
11
hours
2.5
days,
respectively,
among
variants,
especially
second
phase.
These
results
suggest
that
while
exist,
post-peak
all
appeared
be
efficiently
cleared
by
host.
Clinical
Trials
Registration.
NCT04518410.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Июнь 27, 2023
To
compare
the
frequency
of
replication-competent
virologic
rebound
with
and
without
nirmatrelvir-ritonavir
treatment
for
acute
COVID-19.
Secondary
aims
were
to
estimate
validity
symptoms
detect
incidence
emergent
nirmatrelvir-resistance
mutations
after
rebound.
JAMA,
Год журнала:
2023,
Номер
330(16), С. 1519 - 1519
Опубликована: Сен. 29, 2023
In
this
Viewpoint,
the
authors
summarize
therapeutic
landscape
for
COVID-19,
discuss
who
is
most
likely
to
benefit
from
treatment,
provide
an
update
on
managing
illness
in
immunocompromised
individuals,
and
highlight
how
improve
COVID-19
treatment.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 16, 2024
Abstract
In
a
subset
of
SARS-CoV-2
infected
individuals
treated
with
the
oral
antiviral
nirmatrelvir-ritonavir,
virus
rebounds
following
treatment.
The
mechanisms
driving
this
rebound
are
not
well
understood.
We
used
mathematical
model
to
describe
longitudinal
viral
load
dynamics
51
20
whom
rebounded.
Target
cell
preservation,
either
by
robust
innate
immune
response
or
initiation
nirmatrelvir-ritonavir
near
time
symptom
onset,
coupled
incomplete
clearance,
appear
be
main
factors
leading
rebound.
Moreover,
occurrence
is
likely
influenced
treatment
relative
progression
infection,
earlier
treatments
higher
chance
Finally,
our
demonstrates
that
extending
course
treatment,
in
particular
10-day
regimen,
may
greatly
diminish
risk
for
people
mild-to-moderate
COVID-19
and
who
at
high
severe
disease.
Altogether,
results
suggest
some
individuals,
standard
5-day
starting
around
onset
completely
eliminate
virus.
Thus,
after
ends,
can
if
an
effective
adaptive
has
fully
developed.
These
findings
on
role
target
preservation
clearance
also
offer
possible
explanation
other
SARS-CoV-2.
Importance
Nirmatrelvir-ritonavir
initial
reduction
followed
once
stopped.
show
timing
influence
stops
growth
preserves
cells
but
lead
full
adequately
developed,
remaining
Our
provide
insights
into
help
develop
better
strategies
minimize
possibility.
Acta Naturae,
Год журнала:
2024,
Номер
15(4), С. 83 - 91
Опубликована: Янв. 17, 2024
The
coronavirus
disease
(COVID-19)
pandemic
has
brought
into
sharp
relief
the
threat
posed
by
coronaviruses
and
laid
foundation
for
a
fundamental
analysis
of
this
viral
family,
as
well
search
effective
anti-COVID
drugs.
Work
is
underway
to
update
existent
vaccines
against
COVID-19,
screening
low-molecular-weight
drug
candidates
outpatient
medicine
continues.
opportunities
ways
accelerate
development
antiviral
drugs
other
pathogens
are
being
discussed
in
context
preparing
next
pandemic.
In
2012–2015,
Tsyshkova
et
al.
synthesized
group
water-soluble
compounds
exhibiting
an
activity,
whose
chemical
structure
was
similar
that
arbidol.
Among
those,
there
were
number
based
on
5-methoxyindole-3-carboxylic
acid
aminoalkyl
esters.
Only
one
member
rather
extensive
compounds,
dihydrochloride
6-bromo-5-methoxy-1-methyl-2-(1-piperidinomethyl)-3-(2-diethylaminoethoxy)carbonylindole,
exhibited
reliable
effect
SARS-CoV-2
vitro.
At
concentration
52.0
μM,
compound
completely
inhibited
replication
virus
with
infectious
activity
106
TCID50/mL.
curves
analyzed
indicate
specificity
its
action.
Interferon-inducing
suppression
syncytium
formation
induced
spike
protein
(S-glycoprotein)
89%,
also
revealed.
view
synthetic
accessibility
−
high
(IC50
=
1.06
µg/mL)
selectivity
index
(SI
78.6)
appears
meets
requirements
COVID-19
prevention
treatment.
The Journal of Infectious Diseases,
Год журнала:
2023,
Номер
228(Supplement_2), С. S136 - S143
Опубликована: Авг. 31, 2023
Understanding
variant-specific
differences
in
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
viral
kinetics
may
explain
transmission
efficiency
and
provide
insights
on
pathogenesis
prevention.
We
evaluated
SARS-CoV-2
from
nasal
swabs
across
multiple
variants
(Alpha,
Delta,
Epsilon,
Gamma)
placebo
recipients
of
the
ACTIV-2/A5401
trial.
Delta
variant
infection
led
to
highest
maximum
load
shortest
time
symptom
onset
peak.
There
were
no
significant
clearance
variants.
Viral
decline
was
biphasic
with
first-
second-phase
decays
having
half-lives
11
hours
2.5
days,
respectively,
among
variants,
especially
second
phase.
These
results
suggest
that
while
exist,
post-peak
all
appeared
be
efficiently
cleared
by
host.
Clinical
Trials
Registration.
NCT04518410.
